 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on May 09, 2024 |
| Title |
Repurposing niclosamide in mouse models of amyotrophic lateral sclerosis |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
ALS is a complex neurodegenerative disease influenced by genetic, epigenetic, and environmental factors, resulting in dysfunction in cellular and molecular pathways. The limited efficacy of current treatments highlights the need for combination therapies targeting multiple aspects of the disease. Niclosamide, an anthelminthic drug listed as an essential medicine, has been repurposed in clinical trials due to its anti-inflammatory and anti-fibrotic properties. Niclosamide can inhibit various molecular pathways (such as STAT3 and mTOR) that are dysregulated in ALS, suggesting its potential to disrupt these altered mechanisms associated with the pathology. Our recent findings have demonstrated that niclosamide can effectively inhibit inflammatory and fibrotic molecular pathways in ALS models. We administered niclosamide intraperitoneally to two transgenic murine models, FUS and SOD1-G93A mice, which replicate key pathologies and biological processes of ALS. The treatment was initiated at the onset of symptoms, and we assessed the progression of the disease by neurological scores, rotarod and grip tests, as well as monitoring survival. Additionally, we examined the effects of the treatment on spinal cord and muscle degeneration in the treated mice. In both models, the administration of niclosamide resulted in a slowdown of disease progression, an increase in survival rates, and an improvement in tissue pathology. This was characterized by a reduction in gliosis, motor neuron loss, muscle atrophy, and inflammatory markers. Based on these results, our findings demonstrate that niclosamide can impact multiple pathways involved in ALS. This multi-targeted approach leads to a slowdown in the progression of the disease, thereby positioning niclosamide as a promising candidate for repurposing in the treatment of ALS.
|
| |
|
| Overall design |
Gene expression analysis of spinal cord from niclosamide (Nic)and control vehicle (Veh)-treated SOD1-G93A mice at the end stage and symptomatic phase of the disease. A total of n=14 samples were analysed by RNA seq: n=4 end stage Nic, n=4 end stage Veh, n=3 symptomatic Nic, n=3 symptomatic Veh.
|
| |
|
| Contributor(s) |
Milani M, Della Valle I, Rossi S, Fabbrizio P, Margotta C, Nardo G, Cozzolino M, D'Ambrosi N, Apolloni S |
| Citation(s) |
38493058 |
| |
| Submission date |
Nov 30, 2023 |
| Last update date |
May 09, 2024 |
| Contact name |
Savina Apolloni |
| E-mail(s) |
savina.apolloni@uniroma2.it
|
| Organization name |
University of Rome Tor Vergata
|
| Department |
Department of Biology
|
| Street address |
Via della Ricerca Scientifica, 1
|
| City |
Rome |
| ZIP/Postal code |
00133 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (14)
|
| GSM7925897 |
spinal cord, veh end stage, rep4 |
| GSM7925898 |
spinal cord, nic end stage, rep1 |
| GSM7925899 |
spinal cord, nic end stage, rep2 |
| GSM7925900 |
spinal cord, nic end stage, rep3 |
| GSM7925901 |
spinal cord, nic end stage, rep4 |
| GSM7925902 |
spinal cord, veh symptomatic, rep1 |
| GSM7925903 |
spinal cord, veh symptomatic, rep2 |
| GSM7925904 |
spinal cord, veh symptomatic, rep3 |
| GSM7925905 |
spinal cord, nic symptomatic, rep1 |
| GSM7925906 |
spinal cord, nic symptomatic, rep2 |
| GSM7925907 |
spinal cord, nic symptomatic, rep3 |
|
| Relations |
| BioProject |
PRJNA1047112 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE249071_ReNicALS_rawCountsWithAnnotations_end_stage.txt.gz |
796.5 Kb |
(ftp)(http) |
TXT |
| GSE249071_raw_counts_sympto.txt.gz |
234.9 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...